Type 2 Diabetes

The likelihood of developing type 2 diabetes can be detected at an early age. 

Earlier diagnosis and treatment prevent complications.

A recently published meta-analysis puts metformin to the test to see how well it lines up against other T2DM “Medication All-Star Team” members. 

The unique benefits of using empagliflozin need to be considered when determining treatments for type 2 patients.

A new phase 3 study on novel SGLT inhibitor shows favorable results in those living with severe renal impairment.

Adequate amounts of magnesium in the diet could reduce the risk of type 2 and cerebral vascular incidents. 

Long-term users of the acid reflux drugs known as Proton Pump Inhibitors (PPIs) have a 24% higher risk of developing type 2 diabetes than non-PPI users. 

This article is part of a live interview with Dr. Engel, Associate Vice President, Cardiometabolic and Women's Health, Merck Research Laboratories.

Can a virtual diabetes clinic (VDC) improve diabetes care? 

Since DPP-4 plays a role in infection for some coronaviruses, there is increased interest in whether patients using DPP-4 inhibitors are at greater pneumonia risk.